文献速递心血管胸部MR

提升肺动脉高压中危分层:CMR衍生的右心室-动脉耦联定量

Enhancing Intermediate-Risk Stratification in Pulmonary Hypertension: CMR-Derived Quantification of Right Ventricular-Arterial Coupling.
PubMed 文献 · Acad Radiol · 2026-04-06

研究回顾性纳入120例肺动脉高压患者,按2022 ESC/ERS四分层模型分为中低危(76例)和中高危(44例),评估CMR衍生的每搏输出量与收缩末期容积比(SV/ESV)的预后价值。中位随访62个月,33例(28%)发生临床恶化;SV/ESV<0.51者预后显著更差(Log-rank P=0.001),将SV/ESV纳入四分层模型使Harrell C指数从0.60提升至0.74,AIC从289降至272(ΔC=0.14,P=0.008)。

要点

  • 中高危组较中低危组右室收缩功能更差、右室容积更大、左室容积更小、SV/ESV更低(均P<0.05)。
  • SV/ESV<0.51的患者临床恶化风险显著更高(Log-rank P=0.001)。
  • SV/ESV独立预测中高危风险,加入四分层模型后C指数由0.60升至0.74。

核心结论

  • SV/ESV可能作为一种无创生物标志物,为中危肺动脉高压患者的临床恶化提供增量预后价值。

研究设计与样本

  • 回顾性纳入120例肺动脉高压患者,均接受CMR、右心导管检查及完整临床数据;按2022 ESC/ERS简化四分层模型分为中低危组(n=76)和中高危组(n=44);复合终点为临床恶化(因充血性心力衰竭住院或死亡)。

关键影像表现/征象

  • 中高危组较中低危组右心室收缩功能显著受损、右心室容积更大、左心室容积更小、SV/ESV更低(均P<0.05)。
  • 中位随访62个月,33例(28%)发生临床恶化。
  • SV/ESV<0.51的患者临床恶化结局显著更差(Log-rank P=0.001)。

诊断标准与关键数值

  • SV/ESV独立预测中高危风险。
  • SV/ESV<0.51为预后不良阈值(Log-rank P=0.001)。
  • 将SV/ESV纳入四分层模型后,Harrell C指数从0.60升至0.74,AIC从289降至272(ΔC=0.14,P=0.008)。

临床应用与阅片要点

  • 对中危肺动脉高压患者,可关注CMR衍生的SV/ESV以辅助识别中高危亚组。
  • SV/ESV<0.51提示临床恶化风险更高,可作为报告中的预后相关指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine whether cardiovascular magnetic resonance (CMR)-derived stroke volume to end-systolic volume ratio (SV/ESV) improves prognostic stratification in pulmonary hypertension (PH) patients classified as intermediate-risk by the 2022 ESC/ERS four-strata model.

METHODS: We retrospectively included patients with PH who underwent CMR, right heart catheterization (RHC) and complete clinical data. Individuals were categorized into intermediate-low (IML) and intermediate-high (IMH) risk groups according to the 2022 ESC/ERS simplified four-strata model. The composite endpoint of clinical worsening (CW) was defined as hospitalization for congestive heart failure or death. Survival analysis and model performance testing assessed the prognostic contribution of SV/ESV.

RESULTS: Among 120 PH patients (IML n = 76; IMH n = 44), the IMH-group demonstrated significantly impaired right ventricular (RV) systolic function, larger RV volumes, lower left ventricular volume, and reduced SV/ESV (all P < 0.05). SV/ESV independently predicted IMH-risk. Over a median follow-up of 62 months, 33 patients (28%) experienced CW. Patients with SV/ESV < 0.51 had significantly worse outcomes (Log-rank P = 0.001). Incorporation of SV/ESV significantly improved prognostic discrimination compared to the four-strata model alone, increasing Harrell's C-index from 0.60 to 0.74 and reducing the Akaike information criterion (AIC) from 289 to 272 (ΔC = 0.14, P = 0.008).

CONCLUSION: SV/ESV may serve as a noninvasive biomarker that provides incremental prognostic value for clinical deterioration in intermediate-risk PH patients.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Tian H, Wu Q, Wang Z, et al. Enhancing Intermediate-Risk Stratification in Pulmonary Hypertension: CMR-Derived Quantification of Right Ventricular-Arterial Coupling. Acad Radiol. 2026. PMID: 41945015. doi:10.1016/j.acra.2026.03.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。